{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:45Z","timestamp":1790109705782,"version":"4.0.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"\n Background:<\/jats:title>\n Spasticity is a pathophysiological outcome of impaired muscle motor activity, primarily the muscle tone. Muscle tone problems are signs of several neurological conditions, such as multiple sclerosis, movement disorders, spine damage, stroke, and traumatic brain injury. Antispasticity therapeutics belong to a class of treatments that restore motor function and muscle tone. There are several routes of therapeutic administration of antispastic medications; among them, the oral drug delivery system plays a significant role.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n The purpose of the study was to present a complete synthesis of the scientific evidence on the safety and efficacy of antispasticity medicines used orally for the management of nonprogressive neurological disorders.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n In order to carry out a comprehensive meta-analysis, the most pertinent scientific studies on the use of oral antispasticity medications to treat non-progressive neurological illnesses were identified. A search was conducted across a number of databases, including SciELO, Cochrane Central Register of Controlled Trials (CENTRAL), and PubMed. MedCalc statistical software was used to perform a meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards for odds ratio across the studies, relative risk, and risk factor analysis.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n In the present study, a total of 252 original records were retrieved from different predefined databases on oral antispasticity drugs and their association with non-progressive neurological disorders. After several screening steps, 12 studies were found to be eligible for meta-analysis. These studies represented different antispasticity therapeutics that were administered via the oral route. Based on the meta-analysis, oral antispasticity drugs were found to be moderately effective (\n P<\/jats:italic>\n < 0.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The findings of the meta-analysis showed that the interventions of tizanidine, diazepam, dantrolene, baclofen, and gabapentin were more effective in tackling spasticity than the control. Therefore, in the treatment of non-progressive neurological diseases, oral antispasticity medications are only modestly effective.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_556_22","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T06:34:19Z","timestamp":1681281259000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Oral Antispasticity Drugs and Non-Progressive Neurological Diseases: A Meta-Analysis on Safety and Efficacy"],"prefix":"10.4103","volume":"15","author":[{"given":"Abdulrahman M.","family":"Alshahrani","sequence":"first","affiliation":[{"name":"Department of Medicine\/Neurology, College of Medicine, Shaqra University, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"R1-20240829","first-page":"28","article-title":"Drug therapy:Spasticity (first of two parts)","volume":"304","author":"Young","year":"1981","journal-title":"N Engl J Med"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4103\/1658-354X.121087","article-title":"Spasticity-Pathogenesis, prevention and treatment strategies","volume":"7","author":"Ghai","year":"2013","journal-title":"Saudi J Anaesth"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00207454.2012.762364","article-title":"Spasticity in multiple sclerosis:Results of a patient survey","volume":"123","author":"Oreja-Guevara","year":"2013","journal-title":"Int J Neurosci"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1600-0404.1988.tb05899.x","article-title":"Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients","volume":"77","author":"Hoogstraten","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"R5-20240829","first-page":"13","article-title":"Pharmacology of phenol in peripheral nerve blocks:A review","volume":"55","author":"Felsenthal","year":"1974","journal-title":"Arch Phys Med Rehabil"},{"issue":"12 Suppl","key":"R6-20240829","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/14737175.2013.865877","article-title":"Advances in the management of multiple sclerosis spasticity:Experiences from recent studies and everyday clinical practice","volume":"13","author":"Pozzilli","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00002018-200427110-00004","article-title":"A benefit-risk assessment of baclofen in severe spinal spasticity","volume":"27","author":"Dario","year":"2014","journal-title":"Drug Saf"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S0317167100023994","article-title":"The use of baclofen in treatment of spasticity in multiple sclerosis","volume":"6","author":"Sawa","year":"1979","journal-title":"Can J Neurol Sci"},{"key":"R9-20240829","first-page":"398","article-title":"A controlled trial of baclofen in children with cerebral palsy","volume":"5","author":"Milla","year":"1997","journal-title":"J Int Med Res"},{"key":"R10-20240829","first-page":"384","article-title":"Dantrolene sodium in children with spasticity","volume":"55","author":"Haslam","year":"1974","journal-title":"Arch Phys Med Rehabil"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1469-8749.1980.tb03742.x","article-title":"Dantrolene sodium suspension in treatment of spastic cerebral palsy","volume":"22","author":"Joynt","year":"1980","journal-title":"Dev Med Child Neurol"},{"key":"R12-20240829","first-page":"44","article-title":"Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury","volume":"44","author":"Nance","year":"1994","journal-title":"Neurology"},{"key":"R13-20240829","first-page":"19","article-title":"A double blind, cross-over trial of Valium in the treatment of spasticity","volume":"10","author":"Corbett","year":"1972","journal-title":"Paraplegia"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/sj.sc.3100481","article-title":"Gabapentin for the treatment of spasticity in patients with spinal cord injury","volume":"35","author":"Gruenthal","year":"1997","journal-title":"Spinal Cord"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1185\/03007998809111122","article-title":"A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia","volume":"10","author":"Bes","year":"1988","journal-title":"Curr Med Res Opin"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1185\/03007998909110141","article-title":"A double-blind, long-term study of tizanidine (\u201cSirdalud\u201d) in spasticity due to cerebrovascular lesions","volume":"11","author":"Medici","year":"1989","journal-title":"Curr Med Res Opin"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1185\/03007998409109576","article-title":"Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function","volume":"9","author":"Ketel","year":"1984","journal-title":"Curr Med Res Opin"},{"key":"R18-20240829","first-page":"323","article-title":"Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo","volume":"17","author":"Medaer","year":"1991","journal-title":"Acta Ther"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/apmr.2001.25141","article-title":"Prospective assessment of tizanidine for spasticity due to acquired brain injury","volume":"82","author":"Meythaler","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"key":"R20-20240829","first-page":"4","article-title":"Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident:A randomized double blind controlled study","volume":"73","author":"Katrak","year":"1992","journal-title":"Arch Phys Med Rehabil"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_556_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:46Z","timestamp":1787166886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_556_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_556_22","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2022-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}